KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Neogenomics (NEO) Shares Outstanding (2016 - 2026)

Neogenomics filings provide 17 years of Shares Outstanding readings, the most recent being $129.7 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding rose 1.01% to $129.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $129.7 million, a 1.01% increase, with the full-year FY2025 number at $129.0 million, up 0.66% from a year prior.
  • Shares Outstanding hit $129.7 million in Q1 2026 for Neogenomics, up from $129.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $129.7 million in Q1 2026 to a low of $124.7 million in Q1 2022.
  • Median Shares Outstanding over the past 5 years was $127.4 million (2024), compared with a mean of $127.6 million.
  • Biggest five-year swings in Shares Outstanding: increased 6.48% in 2022 and later increased 0.18% in 2024.
  • Neogenomics' Shares Outstanding stood at $126.9 million in 2022, then increased by 0.36% to $127.4 million in 2023, then rose by 0.61% to $128.1 million in 2024, then rose by 0.66% to $129.0 million in 2025, then rose by 0.52% to $129.7 million in 2026.
  • The last three reported values for Shares Outstanding were $129.7 million (Q1 2026), $129.0 million (Q4 2025), and $128.9 million (Q3 2025) per Business Quant data.